Non-invasive observation of repeated adenoviral GFP gene delivery to the anterior segment of the monkey eye in vivo

Journal of Gene Medicine

Volumn 3, Issue 5, 2001, Pages 437-449

  Borrás, Teresa ^a   Gabelt, B'Ann T ^b   Klintworth, Gordon K ^a   Peterson, John C ^b   Kaufman, Paul L ^b  

^a DUKE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adenoviral vectors; Glaucoma; Monkeys; Repeated gene transfer; Trabecular meshwork

Indexed keywords

MACACA FASCICULARIS; PRIMATES; RODENTIA;

GREEN FLUORESCENT PROTEIN; PHOTOPROTEIN; PRIMER DNA;

ADENOVIRUS; ANIMAL; ARTICLE; CHEMISTRY; FEMALE; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; GONIOSCOPY; INTRAOCULAR PRESSURE; MACACA; MALE; METABOLISM; METHODOLOGY; ORGAN CULTURE TECHNIQUE; PHOTOGRAPHY; POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK; TRANSGENE;

ADENOVIRIDAE; ANIMALS; DNA PRIMERS; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GONIOSCOPY; GREEN FLUORESCENT PROTEINS; INTRAOCULAR PRESSURE; LUMINESCENT PROTEINS; MACACA FASCICULARIS; MALE; ORGAN CULTURE TECHNIQUES; PHOTOGRAPHY; POLYMERASE CHAIN REACTION; TRABECULAR MESHWORK; TRANSGENES;

EID: 0035459495     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.210     Document Type: Article

References (68)

1. Quigley HA. Number of people with glaucoma worldwide [see comments] [Review]. Br J Ophthalmol 1996; 80: 389-393.
2. Kupfer C, Underwood B, Gillen T. Leading causes of visual impairment worldwide. In Principles and Practice of Ophthalmology, Albert DM, Jakobiec FA (eds). WB Saunders: Philadelphia, PA, 1994; 1249-1255.
3. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey [see comments]. JAMA 1991; 266: 369-374.
4. Leske MC, Connell AM, Wu SY, et al. Distribution of intraocular pressure. The Barbados Eye Study. Arch Ophthalmol 1997; 115: 1051-1057.
5. Quigley HA, Enger C, Katz J, et al. Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994; 112: 644-649.
6. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study. Ophthalmology 1992; 99: 1499-1504.
7. Goldberg I. Compliance. In Glaucoma Therapy, Ritch R, Shields MB, Krupin T (eds). CV Mosby: St Louis, MO, 1996; 1375-1384.
8. Rohen JW, Zypen EVD. The phagocytic activity of the trabecular meshwork endothelium. An electron-microscopic study of the vervet (Cercopithecus aethiops). Albrecht Von Graefes Arch Klin Exp Ophthalmol 1968; 175: 143-160.
9. Polansky JR, Wood IS, Maglio MT, et al. Trabecular meshwork cell culture in glaucoma research: evaluation of biological activity and structural properties of human trabecular cells in vitro. Ophthalmology 1984; 91: 580-595.
10. Bill A. The drainage of aqueous humor [Editorial]. Invest Ophthalmol 1975; 14: 1-3.
11. Liu X, Brandt CR, Gabelt BT, et al. Herpes simplex virus mediated gene transfer to primate ocular tissues. Exp Eye Res 1999; 69: 385-395.
12. Borrás T, Tamm ER, Zigler Jr JS. Ocular adenovirus gene transfer varies in efficiency and inflammatory response. Invest Ophthalmol Vis Sci 1996; 37: 1282-1293.
13. Bennett J, Tanabe T, Sun D, et al. Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat Med 1996; 2: 649-654.
14. Borrás T, Matsumoto Y, Epstein DL, et al. Gene transfer to the human trabecular meshwork by anterior segment perfusion, invest Ophthalmol Vis Sci 1998; 39: 1503-1507.
15. Borrás T, Rowlette LL, Erzurum SC, et al. Adenoviral reporter gene transfer to the human trabecular meshwork does not alter aqueous humor outflow. Relevance for potential gene therapy of glaucoma. Gene Ther 1999; 6: 515-524.
16. Bennett J, Wilson J, Sun D, et al. Adenovirus vector-mediated in vivo gene transfer into adult murine retina. Invest Ophthalmol Vis Sci 1994; 35: 2535-2542.
17. Graham FL, Prevec L. Manipulation of adenoviral vectors. In Methods in Molecular Biology, Murray EJ (ed.). Humana Press: Clifton, NJ, 1991; 109-128.
18. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes [Review]. Biotechniques 1988; 6: 616-629.
19. Rosenfeld MA, Yoshimura K, Trapnell BC, et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
20. Rosenfeld MA, Siegfried W, Yoshimura K, et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo [see comments]. Science 1991; 252: 431-434.
21. Kozarsky KF, Jooss K, Donahee M, et al. Effective treatment of familial hypercholesterolaemia in the mouse model using adenovirus-mediated transfer of the VLDL receptor gene [published erratum appears in Nat Genet 1996; 13: 374]. Nat Genet 1996; 13: 54-62.
22. Akli S, Caillaud C, Vigne E, et al. Transfer of a foreign gene into the brain using adenovirus vectors [see comments]. Nat Genet 1993; 3: 224-228.
23. Setoguchi Y, Jaffe HA, Danel C, et al. Ex vivo and in vivo gene transfer to the skin using replication-deficient recombinant adenovirus vectors. J Invest Dermatol 1994; 102: 415-421.
24. Ragot T, Vincent N, Chafey P, et al. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 1993; 361: 647-650.
25. Budenz DL, Bennett J, Alonso L, et al. In vivo gene transfer into murine corneal endothelial and trabecular meshwork cells. Invest Ophthalmol Vis Sci 1995; 36: 2211-2215.
26. Hoffman LM, Maguire AM, Bennett J. Cell-mediated immune response and stability of intraocular transgene expression after adenovirus-mediated delivery. Invest Ophthalmol Vis Sci 1997; 38: 2224-2233.
27. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccines [Review]. Biotechnology 1992; 20: 363-390.
28. Graham FL. Adenoviruses as expression vectors and recombinant vaccines [Review]. Trends Biotechnol 1990; 8: 85-87.
29. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells [Review]. Adv Pharmacol 1997; 40: 137-206.
30. Zabner J, Petersen DM, Puga AP, et al. Safety and efficacy of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75-83.
31. Iwamoto HS, Trapnell BC, McConnell CJ, et al. Pulmonary inflammation associated with repeated, prenatal exposure to an E1, E3-deleted adenoviral vector in sheep. Gene Ther 1999; 6: 98-106.
32. Yei S, Mittereder N, Tang K, et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1994; 1: 192-200.
33. Yang Y, Li Q, Ertl HC, et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
34. Dong JY, Wang D, Van G, et al. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7: 319-331.
35. Kaplan JM, St George JA, Pennington SE, et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 1996; 3: 117-127.
36. St George JA, Pennington SE, Kaplan JM, et al. Biological response of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther 1996; 3: 103-116.
37. Schulick AH, Vassalli G, Dunn PF, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997; 99: 209-219.
38. Zsengeller ZK, Wert SE, Hull WM, et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
39. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci U S A 1994; 91: 4407-4411.
40. Dedieu JF, Vigne E, Torrent C, et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71: 4626-4637.
41. Wang Q, Greenburg G, Bunch D, et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Ther 1997; 4: 393-400.
42. Amalfitano A, Hauser MA, Hu H, et al. Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
43. Christ M, Lusky M, Stoeckel F, et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997; 57: 19-25.
44. Lusky M, Christ M, Rittner K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998; 72: 2022-2032.
45. Parks RJ, Evelegh CM, Graham FL. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 1999; 6: 1565-1573.
46. Taylor AW. Neuroimmunomodulation in immune privilege: role of neuropeptides in ocular immunosuppression [Review]. Neuroimmunomodulation 1996; 3: 195-204.
47. Kaufman PL, Lütjen-Drecoll E. Total iridectomy in the primate in vivo: surgical technique and postoperative anatomy. Invest Ophthalmol 1975; 14: 766-771.
48. Kaufman PL, Bárány EH. Loss of acute pilocarpine effect on outflow facility following surgical disinsertion and retrodisplacement of the ciliary muscle from the scleral spur in the cynomolgus monkey. Invest Ophthalmol 1976; 15: 793-807.
49. Kaufman PL, Bárány EH. Residual pilocarpine effects on outflow facility after ciliary muscle disinsertion in the cynomolgus monkey. Invest Ophthalmol 1976; 15: 558-561.
50. Bárány EH. Simultaneous measurements of changing intraocular pressure and outflow facility in the vervet monkey by constant pressure infusion. Invest Ophthalmol 1964; 3: 135-143.
51. Kaufman PL, Davis GE. "Minified" Goldmann applanating prism for tonometry in monkeys and humans. Arch Ophthalmol 1980; 98: 542-546.
52. Croft MA, Kiland JA, Gange SJ, et al. Comparison of Goldmann tonometry measurements using creamer vs fluorescein in cynomolgus monkeys. In Basic and Clinical Applications of Vision Science, Lakshminarayanan V (ed.). Kluwer: Dordrecht, The Netherlands, 1997; 213-216.
53. Wessing A. Fluorescein Angiography of the Retina. CV Mosby: St Louis, MO, 1969.
54. Brann T, Kayda D, Lyons RM, et al. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in nonhuman primates. Hum Gene Ther 1999; 10: 2999-3011.
55. Loser P, Jennings GS, Strauss M, et al. Reactivation of the previously silenced cytomegalovirus major immediate-early promoter in the mouse liver: involvement of NFkappaB. J Virol 1998; 72: 180-190.
56. Liu HS, Jan MS, Chou CK, et al. Is green fluorescent protein toxic to the living cells? Biochem Biophys Res Commun 1999; 260: 712-717.
57. Tons CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987; 28: 477-481.
58. Sagara T, Gaton DD, Lindsey JD, et al. Reduction of collagen type I in the ciliary muscle of inflamed monkey eyes. Invest Ophthalmol Vis Sci 1999; 40: 2568-2576.
59. Wu N, Ataai MM. Production of viral vectors for gene therapy applications. Curr Opin Biotechnol 2000; 11: 205-208.
60. Engelhardt JF, Simon RH, Yang Y, et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: biological efficacy study. Hum Gene Ther 1993; 4: 759-769.
61. Simon RH, Engelhardt JF, Yang Y, et al. Adenovirus-mediated transfer of the CFTR gene to lung of nonhuman primates: toxicity study. Hum Gene Ther 1993; 4: 771-780.
62. Yei S, Mittereder N, Wert S, et al. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum Gene Ther 1994; 5: 731-744.
63. Ginsberg HS, Horswood RL, Chanock RM, et al. Role of early genes in pathogenesis of adenovirus pneumonia [published erratum appears in Proc Natl Acad Sci U S A 1991; 88: 681]. Proc Natl Acad Sci U S A 1990; 87: 6191-6195.
64. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987; 28: 477-481.
65. Sagara T, Gaton DD, Lindsey JD, et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch Ophthalmol 1999; 117: 794-801.
66. Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998; 67: 179-191.
67. Gabelt BT, Kaufman PL. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res 1989; 49: 389-402.
68. Rohen JW. Morphology of the uveal tract. In The Uveal Tract and its Endogenous Inflammations, Remky H (ed.). Little, Brown & Company: Boston, MA, 1965; 581-667.